BioMarin Collaborates with Skyline to Develop and Commercialize AAV Gene Therapies for Genetic Cardiovascular Diseases
Shots:
- Skyline to receive an upfront along with equity investment & is eligible to receive pre-specified fees for R&D, regulatory and commercial milestones along with royalties on sales in its territories. The companies will advance the programs through clinical development in their pre-defined territories
- BioMarin gets the rights to commercialize therapeutic products in territories, including the US, EU, and Latin America. Skyline will be responsible for commercialization in the Asia-Pacific region
- The collaboration will use Skyline Therapeutics' integrated AAV gene therapy platform & BioMarin’s capabilities to develop gene therapies for the treatment of genetic DCM
Ref: PR Newswire | Image: UCLB
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com